Akums Drugs IPO gets subscribed over 64X by final day, QIB portion booked over 90X

Founded in 2004, Akums Drugs and Pharmaceuticals operates as a prominent pharmaceutical contract development and manufacturing organisation (CDMO).

On August 1, the final day of bidding for Akums Drugs and Pharmaceuticals Ltd's IPO, the issue was overall subscribed 64.4 times. Qualified Institutional Buyers (QIBs) showed the highest demand, subscribing over 90 times their allocated shares. Non-institutional investors (NIIs) followed, subscribing to over 42 times their allotment, while Retail Individual Investors (RIIs) subscribed 20.6 times their allocation. The employee portion was subscribed over 4 times.

The IPO, which aims to raise Rs 1,856.74 crore, opened for subscription on July 30. The shares of the company are expected to debut on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on August 6.

Follow our live blog for all the market action

The IPO comprises a fresh issue of 1 crore shares valued at Rs 680 crore, alongside an offer for sale of 1.73 crore shares amounting to Rs 1,176.74 crore. The price band for the shares is set between Rs 646 and Rs 679.

The IPO has already garnered substantial interest from anchor investors, raising Rs 828.78 crore. The anchor bid date was set for July 29.

The proceeds from the IPO will be directed towards repaying company and subsidiary debts, enhancing working capital, pursuing growth through acquisitions, and addressing general corporate needs.

Also Read | Akums Drugs and Pharmaceuticals mobilises Rs 829 crore via anchor book, IPO opens on July 30

ICICI Securities Ltd, Axis Bank Ltd, Citigroup Global Markets India Pvt Ltd, and Ambit Pvt Ltd are serving as the book-running lead managers for the IPO, with Link Intime India Pvt Ltd as the registrar.

Founded in 2004, Akums Drugs and Pharmaceuticals operates as a prominent pharmaceutical contract development and manufacturing organisation (CDMO). It also manufactures and sells branded drugs and active pharmaceutical ingredients (APIs).

For the fiscal year ending March 31, 2024, Akums reported a 13.81 percent increase in revenue. However, the company saw 99.19 percent decline in profit after tax (PAT) compared to the previous year.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.